VaxGen’s rPA102 Recombinant Anthrax Vaccine
April 15, 2004 by admin · Leave a Comment
On April 15, 2004 VaxGen, Inc. announced that it had started the Phase II clinical testing of rPA102, its recombinant anthrax vaccine. VaxGen indicated that this 13-month trial is one of two studies under a $80.3 million agreement with the NIH’s National Institute of Allergy and Infectious diseases. The purpose of this study, involving 480 [...]
DAC GLP-1 for Type II Diabetes
April 12, 2004 by admin · 2 Comments
On April 12, 2004 ConjuChem Inc. announced interim Phase II results for DAC™: GLP-1. The company released results for patients who had received the first 28 days of therapy of the planned 3 month trial. Based on approximately 80 patients to date, ConjuChem reported a statistically significant reduction in Hgb A1C and glucose normalization or [...]
Zenapax (daclizumab)
March 19, 2004 by admin · Leave a Comment
On March 15, 2004 Protein Design Labs, Inc. reported results from the initial clinical study of the humanized antibody daclizumab in patients with chronic, persistent asthma whose disease was not well controlled with high doses of inhaled corticosteroid therapy. This Phase II randomized, double-blind, placebo-controlled clinical trial was conducted at 24 centers in the United [...]
Avastin
February 6, 2004 by admin · Leave a Comment
n early December 2003, Genentech announced that the Biologics License Application (BLA) for Avastin (bevacizumab) as a first line therapy in metastatic colorectal cancer had been submitted to the FDA. Genentech requested and received a ‘Priority Review’ designation.